Cyclerion Therapeutics, Inc.

NasdaqCM:CYCN Voorraadrapport

Marktkapitalisatie: US$3.6m

Cyclerion Therapeutics Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEOno data
Eigendom CEOn/a
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuur3.8yrs

Recente managementupdates

Recent updates

Cyclerion stock tanks 32% on workforce reduction, clinical development refocus

Oct 06

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Aug 09
We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Mar 03
We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders

Oct 26

Cyclerion Therapeutics: Insiders Buying With No Clinical Data Due Until YE 2021

Jun 21

Cyclerion climbs on a series of insider purchases

Jun 08

Cyclerion updates on clinical trial progress at webinar

Apr 28

Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

Mar 09
Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?

Jan 28
What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?

Cyclerion Therapeutics +10.5% after prelim reports

Jan 13

Cyclerion Therapeutics announces promotions

Dec 21

Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?

Dec 20
Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?

Cyclerion Therapeutics reports Q3 results

Nov 05

CEO

Cyclerion Therapeutics heeft geen CEO, of we hebben geen gegevens over hen.


Bestuursleden

NaamPositieTenureCompensatieEigendom
Peter Hecht
Director5.6yrsUS$169.80k15%
$ 535.9k
Errol De Souza
Independent Chairman3.6yrsUS$131.08k1.99%
$ 71.0k
Harald H. H. Schmidt
Member of Scientific Advisory Board3.8yrsgeen gegevensgeen gegevens
Steven Hyman
Independent Director2.3yrsUS$57.30k0.79%
$ 28.4k
Michael Higgins
Independent Directorless than a yearUS$43.60k0.79%
$ 28.4k
Robert Malenka
Member of Scientific Advisory Board3.8yrsgeen gegevensgeen gegevens
Daniela Salvemini
Member of Scientific Advisory Board3.8yrsgeen gegevensgeen gegevens
Mark Currie
Chair of Scientific Advisory Boardno dataUS$366.78kgeen gegevens
Andrew Budson
Member of Clinical Advisory Board3.8yrsgeen gegevensgeen gegevens
Eric Smith
Member of Clinical Advisory Board3.8yrsgeen gegevensgeen gegevens
M Westover
Member of Clinical Advisory Board3.8yrsgeen gegevensgeen gegevens
David Salat
Member of Clinical Advisory Board3.8yrsgeen gegevensgeen gegevens

3.8yrs

Gemiddelde duur

69yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CYCN wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).